^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serine protease inhibitor

    Related drugs:
    1d
    A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation (clinicaltrials.gov)
    P=N/A, N=140, Recruiting, Beijing Chao Yang Hospital | N=60 --> 140
    Enrollment change
    |
    nafamostat
    4d
    Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. (PubMed, Kidney Med)
    Daratumumab-based induction therapy resulted in a partial renal response (urinary protein-creatinine ratio of 0.7 g/g)...To our knowledge, this case represents only the second reported case of HTRA1-MN occurring in the setting of monoclonal gammopathy, the first in multiple myeloma, and a rare example of a nonmonotypic MN in this context. Temporal proximity and partial response to anti-plasma cell therapy suggest a possible paraneoplastic relationship, although a causal relationship remains unproven.
    Journal
    |
    HTRA1 (HtrA Serine Peptidase 1)
    |
    Darzalex (daratumumab)
    8d
    Nebulized Versus Intravenous Tranexamic Acid for the Management of Hemoptysis (clinicaltrials.gov)
    P3, N=170, Not yet recruiting, Assiut University
    New P3 trial
    15d
    IVTXA: Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy (clinicaltrials.gov)
    P2, N=150, Recruiting, University of California, San Francisco | Trial completion date: May 2026 --> May 2032 | Trial primary completion date: May 2026 --> May 2032
    Trial completion date • Trial primary completion date
    15d
    EFFECT OF TRANEXAMIC ACID ON PERIOPERATIVE BLOOD LOSS IN REAMED INTRAMEDULLARY NAILING OF DIAPHYSEAL FEMORAL AND TIBIAL FRACTURES: A PROSPECTIVE COMPARATIVE STUDY (clinicaltrials.gov)
    P=N/A, N=54, Completed, Kathmandu University School of Medical Sciences
    New trial
    22d
    Combined Tranexamic Acid Use in Total Hip Replacement Surgery (clinicaltrials.gov)
    P=N/A, N=58, Completed, St. Anne's University Hospital Brno, Czech Republic
    New trial
    23d
    TEAPOT Study Multisite (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, The University of Texas Health Science Center at San Antonio | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    24d
    Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) (clinicaltrials.gov)
    P1, N=54, Recruiting, Ensysce Biosciences | N=30 --> 54 | Trial completion date: Dec 2026 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    1m
    Tranexamic Acid in Pediatric Idiopathic Scoliosis Surgery (clinicaltrials.gov)
    P=N/A, N=90, Not yet recruiting, Poznan University of Medical Sciences
    New trial
    1m
    Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis (clinicaltrials.gov)
    P1, N=60, Recruiting, Vanderbilt University Medical Center | Trial completion date: Feb 2026 --> Apr 2029 | Trial primary completion date: Feb 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    2ms
    TEAPOT Study Multisite (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, The University of Texas Health Science Center at San Antonio
    New P1 trial
    2ms
    CamKid: Effect Camostat for Kidney Protection in Chronic Kidney Disease (clinicaltrials.gov)
    P2, N=40, Recruiting, Odense University Hospital | Completed --> Recruiting
    Enrollment open